Leukocyte-removing filtering membrane for platelet-rich suspension and preparation method of leukocyte-removing filtering membrane
Through the coaxial electrospinning process of polyethersulfone-polylactic acid filter membrane and the surface grafting technology of vinylpyrrolidone-acrylamide copolymer, the risk of platelet activation and leukocyte filtration rate of platelet-rich leukocyte filters in the prior art are solved. The problem of low efficiency of platelet recovery and leukocyte filtration is achieved, and the biocompatibility and antibacterial properties of the material are improved.
Patent Information
- Application Number
- CN202411000458.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-25
AI Technical Summary
The existing platelet-rich leukocyte deletion filters have the risks of platelet activation, complex operation, low leukocyte filtration rate and insufficient biocompatibility of materials, especially polybutylene terephthalate meltblown nonwoven materials on platelets. During enrichment, platelets are easily activated and the pore size distribution is wide, making it difficult to achieve a 99.5% leukocyte filtration rate.
The polyethersulfone-polylactic acid filter membrane was prepared by coaxial electrospinning process, combined with vinylpyrrolidone-acrylamide copolymer surface graft, nanotitanium dioxide and hydrophilic modifier were added to prepare uniform pore size and high hydrophilicity. , platelet-rich suspension with good antibacterial properties removes leukocyte filtration membrane.
The filtration rate of white blood cells in platelet suspension reached 99%, the platelet yield reached more than 95%, and it has good biocompatibility and antibacterial properties, reducing the risk of bacterial contamination.
Smart Images

Figure CN118904121A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a filter membrane and a preparation method thereof, in particular to a leukocyte-removing filter membrane for platelet-rich suspension and a preparation method thereof. Background Art
[0002] Platelets play multiple key roles in the medical field, including hemostasis and coagulation, blood transfusion for the treatment of thrombocytopenic diseases, promotion of wound healing and tissue repair, and prevention and treatment of cardiovascular and cerebrovascular diseases. With the development of medical technology, the market demand for platelet-rich plasma (PRP) and leukocyte-reduced platelet products continues to grow, indicating that platelet-related products have broad application prospects and market potential in the future medical and health industry. As a result, the demand for platelet-rich leukocyte-reduced filters that are easy to operate and have high leukocyte removal rates is also growing.
[0003] At present, the commonly used platelet collection methods include manual separation and single-collection platelet enrichment. Although targeted collection can be carried out according to clinical needs, the overall quality of the platelet preparations is not high due to differences in personnel skills and low leukocyte removal rate (generally only 1log level). Other methods such as machine-collected platelets, washing methods and gel filtration methods have more or less platelet activation risks and complex operations.
[0004] Common filters for whole blood leukocyte removal usually use melt-blown nonwoven fabrics modified from polybutylene terephthalate as filter membrane materials. This material has the advantages of finer fibers, relatively small pore size, better biocompatibility, and low price. However, when this material is used for platelet enrichment, it often has problems such as easy activation of platelets and low platelet yield. The platelet-rich suspension leukocyte filters currently on the market that use melt-blown PBT filter membranes have the problems of large average pore size and wide pore size distribution, and the leukocyte removal rate is difficult to exceed 99.5%.
[0005] Chinese patent CN110787647A discloses the preparation of a platelet-leukocyte-removing filter membrane, which uses a 10-20% grafting rate of acrylate-modified PBT melt-blown non-woven fabric as a base fabric, and immerses it in a prepolymer solution of vinyl pyrrolidone and vinyl acetate to obtain a filter membrane with a leukocyte removal rate of more than 99.9%. However, the biocompatibility of the vinyl acetate itself is poor, and it is classified in the list of Class 2B carcinogens, and the filter membrane obtained has certain safety hazards.
[0006] Chinese patent CN104923091B discloses the preparation of a leukocyte filtration membrane with high leukocyte retention rate, high platelet permeability and low hemolysis rate. The patent uses PBT melt-blown non-woven fabric as the base fabric, immerses the non-woven fabric in a mixed solution containing a grafting modifier, an inhibitor and an initiator, and uses gamma-ray irradiation to prepare a leukocyte filtration membrane with a grafting rate of 5 to 15%, thereby obtaining a filter membrane with a pore size of 30 to 50 μm, a leukocyte removal rate of 99.6%, and a platelet recovery rate of 89.7%. However, the preparation process uses gamma-ray irradiation cross-linking, which has strict requirements on production conditions in the industrial application process, and it is difficult to control the grafting rate. Summary of the invention
[0007] In view of this, and in view of the deficiencies of the prior art, the present invention provides a leukocyte-removing filter membrane for platelet-rich suspension and a preparation method thereof.
[0008] A platelet-rich suspension leukocyte-removing filter membrane and a preparation method thereof, comprising the following steps:
[0009] S1: Preparation of polyethersulfone-polylactic acid filter membrane, dissolving 15-30g polyethersulfone in 50-150g organic solvent A to obtain a polyethersulfone solution, adding 10-20g polylactic acid, 0.3-1g nano-titanium dioxide and 0.5-2g hydrophilic modifier into 50-150g organic solvent B and stirring to obtain a polylactic acid solution, using a coaxial electrospinning process, using the polyethersulfone solution and the polylactic acid solution to simultaneously spin, to prepare a polyethersulfone-polylactic acid filter membrane with polyethersulfone as the core layer and polylactic acid as the skin layer;
[0010] S2: Preparation of platelet-rich suspension leukocyte-removing filter membrane, dissolve 5-10g vinyl pyrrolidone and 10-20g acrylamide in 800-1000mL deionized water to obtain a mixed solution, completely immerse the polyethersulfone-polylactic acid filter membrane in the mixed solution, drop an initiator into the mixed solution immersed in the polyethersulfone-polylactic acid filter membrane, the initiator amount is 3-6% of the total mass of vinyl pyrrolidone and acrylamide, seal the reaction, and after the reaction is completed, filter, rinse and dry to obtain a platelet-rich suspension leukocyte-removing filter membrane.
[0011] Furthermore, step S1 polyethersulfone-polylactic acid filter membrane preparation specifically includes the following steps:
[0012] S1.1: 15-30 g of polyethersulfone is placed in 50-150 g of organic solvent A, and magnetically stirred at 200-600 rpm for 20-50 min until the polyethersulfone is completely dissolved to obtain a polyethersulfone solution;
[0013] S1.2: 10-20 g of polylactic acid, 0.3-1 g of nano-titanium dioxide and 0.5-2 g of a hydrophilic modifier are placed in 50-150 g of an organic solvent B, and magnetically stirred at 200-600 rpm for 20-50 min until the polylactic acid and the hydrophilic modifier are completely dissolved to obtain a polylactic acid solution;
[0014] S1.3: Take the polylactic acid solution and the polyethersulfone solution and inject them into the No. 1 syringe and the No. 2 syringe with a capacity of 10 mL respectively, wherein the polyethersulfone solution is injected into the No. 1 syringe and the polylactic acid solution is injected into the No. 2 syringe. Use a PVDF plastic tube to connect the coaxial spinneret, fix the No. 1 syringe and the No. 2 syringe on the injection pump, set the spinning voltage to 10-30KV, the receiving distance to 10-20cm, the propulsion speed to 0.5-1.5mL / h, and use 304 stainless steel as the receiving substrate for collection to obtain a polyethersulfone-polylactic acid filter membrane with polyethersulfone as the core layer and polylactic acid as the skin layer.
[0015] Furthermore, the organic solvent A is at least one of dimethylformamide, N,N-dimethylacetamide, dichloromethane, acetone and N-methylpyrrolidone.
[0016] Furthermore, the organic solvent B is at least one of N,N-dimethylacetamide, dichloromethane, chloroform, acetone and tetrahydrofuran.
[0017] Furthermore, the hydrophilic modifier is at least one of hydroxymethyl cellulose, hydroxyethyl cellulose and hydroxypropyl cellulose.
[0018] Furthermore, the particle size of nano titanium dioxide is 20 to 60 nm.
[0019] Furthermore, step S2, preparation of a leukocyte-removing filter membrane for platelet-rich suspension, specifically comprises the following steps:
[0020] S2.1: Add 5-10 g of vinyl pyrrolidone and 10-20 g of acrylamide into a reactor filled with 800-1000 mL of deionized water, stir magnetically for 10-20 min at 200-600 rpm to mix well, and obtain a mixed solution;
[0021] S2.2: The polyethersulfone-polylactic acid filter membrane is completely immersed in the mixed solution, and nitrogen is introduced into the reactor for deoxygenation treatment. The ventilation time is 20 to 30 minutes. Then, an initiator is dripped into the reactor. The amount of the initiator is 3 to 6% of the mass of vinyl pyrrolidone and acrylamide. Then, the reactor is sealed and placed in a constant temperature oil bath at 60 to 80°C for reaction for 0.5 to 2 hours.
[0022] S2.3: After the reaction is completed, the polyethersulfone-polylactic acid filter membrane is filtered out of the reactor and rinsed with deionized water for 3 to 5 times. Then, the rinsed polyethersulfone-polylactic acid filter membrane is placed in an oven at 80°C to dry to obtain a platelet-rich suspension leukocyte-removing filter membrane.
[0023] Furthermore, the initiator is azobisisobutyronitrile, potassium persulfate, azobisisobutylimidazoline hydrochloride or azobiscyanovaleric acid.
[0024] A leukocyte-removing filter membrane for platelet-rich suspension is prepared by the preparation method of the leukocyte-removing filter membrane for platelet-rich suspension.
[0025] Furthermore, the platelet-rich suspension leukocyte-removing filter membrane is stacked into 3 to 10 layers to prepare a PF type leukocyte filter for filtering leukocytes in the platelet-rich suspension and recovering platelets.
[0026] The present invention has the following advantages:
[0027] 1. In the present invention, a polyethersulfone material with stable mechanical properties, heat resistance and chemical properties is used as the core material, and polylactic acid with good biocompatibility and safety is used as the skin material. A coaxial electrospinning process is adopted to prepare a polyethersulfone-polylactic acid filter membrane, and then the polyethersulfone-polylactic acid filter membrane is used to prepare a platelet-rich suspension leukocyte-removing filter membrane. The platelet-rich suspension leukocyte-removing filter membrane has the characteristics of uniform pore size, narrow pore size distribution and high porosity, which is beneficial to improving the filtration rate of leukocytes in the platelet-rich suspension.
[0028] 2. In the present invention, adding a hydrophilic modifier to the polylactic acid solution can effectively improve the hydrophilicity of the polyethersulfone-polylactic acid filter membrane, improve the platelet recovery rate and the leukocyte removal rate, and adding nano-titanium dioxide to the polylactic acid solution can effectively improve the antibacterial properties of the polyethersulfone-polylactic acid filter membrane, reduce and prevent the risk of bacterial contamination, and thus make the platelet-rich suspension leukocyte-removing filter membrane have good hydrophilicity and antibacterial properties.
[0029] 3. In the present invention, vinyl pyrrolidone-acrylamide copolymer is grafted on the surface of polyethersulfone-polylactic acid filter membrane, which is beneficial to further improve the hydrophilicity and biocompatibility. The obtained platelet-rich suspension leukocyte-removal filter membrane has a leukocyte removal rate of 99% for platelet suspension and a platelet recovery rate of more than 95%. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 This is a scanning electron microscope (SEM) image of the platelet-rich suspension leukocyte-removing filter membrane prepared in Example 1. DETAILED DESCRIPTION
[0031] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0032] Example 1
[0033] A method for preparing a platelet-rich suspension leukocyte-removing filter membrane specifically comprises the following steps:
[0034] S1: Preparation of polyethersulfone-polylactic acid filtration membrane,
[0035] S1.1: 18 g of polyethersulfone was placed in 100 g of dimethylformamide solvent, and magnetically stirred at 400 rpm for 30 min until the polyethersulfone was completely dissolved to obtain a polyethersulfone solution;
[0036] S1.2: 12.6 g of polylactic acid, 0.63 g of nano-titanium dioxide with a particle size of 30 nm and 0.84 g of hydroxyethyl cellulose were placed in 100 g of dichloromethane solvent, and magnetically stirred at 400 rpm for 30 min until the polylactic acid and hydroxyethyl cellulose were completely dissolved to obtain a polylactic acid solution;
[0037] S1.3: Take 10mL of polylactic acid solution and 10mL of polyethersulfone solution and inject them into syringe No. 1 and syringe No. 2 respectively, each with a capacity of 10mL, wherein the polyethersulfone solution is injected into syringe No. 1 and the polylactic acid solution is injected into syringe No. 2, and the syringe No. 1 and No. 2 are connected to the coaxial spinneret by a PVDF plastic tube, and the syringe No. 1 and the syringe No. 2 are fixed on the injection pump, and the spinning voltage is set to 20KV, the receiving distance is 12cm, and the propulsion speed is 1mL / h. 304 stainless steel is used as a receiving substrate for collection, and a polyethersulfone-polylactic acid filter membrane with polyethersulfone as the core layer and polylactic acid as the skin layer is obtained;
[0038] S2: Preparation of leukocyte-removing filter membrane for platelet-rich suspension,
[0039] S2.1: Add 7 g of vinyl pyrrolidone and 14 g of acrylamide into a reactor containing 1000 mL of deionized water, and stir the mixture under magnetic stirring at 200 rpm for 20 min to obtain a mixed solution;
[0040] S2.2: The polyethersulfone-polylactic acid filter membrane obtained in step S1.3 is completely immersed in the mixed solution obtained in step S2.1, and nitrogen is introduced into the reactor for deoxygenation treatment for 30 minutes. Then, 0.84 g of potassium persulfate is dropped into the reactor, and then the reactor is sealed and placed in a 65°C constant temperature oil bath for reaction for 1 hour;
[0041] S2.3: After the reaction is completed, the polyethersulfone-polylactic acid filter membrane after the reaction is filtered out from the reactor, and rinsed with deionized water for 5 times. Then, the rinsed polyethersulfone-polylactic acid filter membrane is placed in an oven at 80°C to dry to obtain a platelet-rich suspension leukocyte-removing filter membrane. Figure 1 This is a scanning electron micrograph of the leukocyte-removing filter membrane for platelet-rich suspension.
[0042] Example 2
[0043] A method for preparing a platelet-rich suspension leukocyte-removing filter membrane specifically comprises the following steps:
[0044] S1: Preparation of polyethersulfone-polylactic acid filtration membrane,
[0045] S1.1: 18 g of polyethersulfone is placed in 100 g of organic solvent A, wherein the organic solvent A is prepared by mixing N,N-dimethylacetamide and dichloromethane in a volume ratio of 8:2, and magnetically stirring at 400 rpm for 30 min until the polyethersulfone is completely dissolved to obtain a polyethersulfone solution;
[0046] S1.2: 12.6 g of polylactic acid, 0.63 g of nano-titanium dioxide with a particle size of 30 nm, and 1.5 g of hydroxypropyl cellulose were placed in 100 g of organic solvent B, wherein the organic solvent B was prepared by mixing N,N-dimethylacetamide and dichloromethane in a volume ratio of 1:9, and magnetically stirred at 400 rpm for 30 min until the polylactic acid and hydroxypropyl cellulose were completely dissolved to obtain a polylactic acid solution;
[0047] S1.3: Take 10mL of polylactic acid solution and 10mL of polyethersulfone solution and inject them into syringe No. 1 and syringe No. 2 respectively, each with a capacity of 10mL, wherein the polyethersulfone solution is injected into syringe No. 1 and the polylactic acid solution is injected into syringe No. 2, and the syringe No. 1 and No. 2 are connected to the coaxial spinneret by a PVDF plastic tube, and the syringe No. 1 and the syringe No. 2 are fixed on the injection pump, and the spinning voltage is set to 20KV, the receiving distance is 12cm, and the propulsion speed is 0.8mL / h. 304 stainless steel is used as a receiving substrate for collection, and a polyethersulfone-polylactic acid filter membrane with polyethersulfone as the core layer and polylactic acid as the skin layer is obtained;
[0048] S2: Preparation of leukocyte-removing filter membrane for platelet-rich suspension,
[0049] S2.1: Add 6 g of vinyl pyrrolidone and 18 g of acrylamide into a reactor filled with 1000 mL of deionized water, and stir the mixture under magnetic stirring at 200 rpm for 20 min to obtain a mixed solution;
[0050] S2.2: The polyethersulfone-polylactic acid filter membrane obtained in step S1.3 is completely immersed in the mixed solution obtained in step S2.1, and nitrogen is introduced into the reactor for deoxygenation treatment for 30 minutes. Then, 0.96 g of azobisisobutylimidazoline hydrochloride is dropped into the reactor. Then, the reactor is sealed and placed in a 65°C constant temperature oil bath for reaction for 1 hour.
[0051] S2.3: After the reaction is completed, the polyethersulfone-polylactic acid filter membrane after the reaction is filtered out from the reactor, and rinsed with deionized water for 5 times. Then, the rinsed polyethersulfone-polylactic acid filter membrane is placed in an oven at 80°C to dry to obtain a platelet-rich suspension leukocyte-removing filter membrane.
[0052] Example 3
[0053] A method for preparing a platelet-rich suspension leukocyte-removing filter membrane specifically comprises the following steps:
[0054] S1: Preparation of polyethersulfone-polylactic acid filtration membrane,
[0055] S1.1: 24 g of polyethersulfone was placed in 100 g of dimethylformamide solvent, and magnetically stirred at 400 rpm for 30 min until the polyethersulfone was completely dissolved to obtain a polyethersulfone solution;
[0056] S1.2: 20 g of polylactic acid, 1 g of nano titanium dioxide with a particle size of 30 nm, and 2 g of a hydrophilic modifier are placed in 100 g of dichloromethane solvent, wherein the hydrophilic modifier is prepared by compounding hydroxypropyl cellulose and hydroxymethyl cellulose in a weight ratio of 1:1, and magnetically stirred at 400 rpm for 30 min until the polylactic acid and the hydroxyethyl cellulose are completely dissolved to obtain a polylactic acid solution;
[0057] S1.3: Take 10mL of polylactic acid solution and 10mL of polyethersulfone solution and inject them into syringe No. 1 and syringe No. 2 respectively, both of which have a capacity of 10mL, wherein the polyethersulfone solution is injected into syringe No. 1 and the polylactic acid solution is injected into syringe No. 2, and the syringe No. 1 and No. 2 are connected to the coaxial spinneret by a PVDF plastic tube, and the syringe No. 1 and the syringe No. 2 are fixed on the injection pump, and the spinning voltage is set to 25KV, the receiving distance is 15cm, and the propulsion speed is 0.8mL / h. 304 stainless steel is used as a receiving substrate for collection, and a polyethersulfone-polylactic acid filter membrane with polyethersulfone as the core layer and polylactic acid as the skin layer is obtained;
[0058] S2: Preparation of leukocyte-removing filter membrane for platelet-rich suspension,
[0059] S2.1: Add 6 g of vinyl pyrrolidone and 18 g of acrylamide into a reactor containing 1000 mL of deionized water, and stir the mixture under magnetic stirring at 200 rpm for 10 min to obtain a mixed solution;
[0060] S2.2: The polyethersulfone-polylactic acid filter membrane obtained in step S1.3 is completely immersed in the mixed solution obtained in step S2.1, and nitrogen is introduced into the reactor for deoxygenation treatment for 30 minutes. Then, 0.96 g of azobiscyanovaleric acid is dropped into the reactor. Then, the reactor is sealed and placed in a 65°C constant temperature oil bath for reaction for 1 hour.
[0061] S2.3: After the reaction is completed, the polyethersulfone-polylactic acid filter membrane after the reaction is filtered out from the reactor, and rinsed with deionized water for 5 times. Then, the rinsed polyethersulfone-polylactic acid filter membrane is placed in an oven at 80°C to dry to obtain a platelet-rich suspension leukocyte-removing filter membrane.
[0062] Comparative Example 1
[0063] Compared with Example 1, the difference of Comparative Example 1 is that the coaxial electrospinning process in step S1.3 is replaced by the traditional single nozzle electrospinning process, and the specific operation is: take 10mL of polylactic acid solution and 10mL of polyethersulfone solution, stir and mix to obtain a polylactic acid-polyethersulfone mixed solution, inject the polylactic acid-polyethersulfone mixed solution into a syringe, fix the syringe on a syringe pump for electrospinning, the spinning voltage is 20KV, the receiving distance is 12cm, and the propulsion speed is 1mL / h to form a polyethersulfone-polylactic acid mixed filter membrane, and the polyethersulfone-polylactic acid filter membrane in step S2.2 is replaced by a polyethersulfone-polylactic acid mixed filter membrane, and the polyethersulfone-polylactic acid mixed filter membrane is surface grafted. The other steps remain unchanged to prepare a platelet-rich suspension leukocyte-removing filter membrane, which is recorded as Comparative Example 1.
[0064] Comparative Example 2
[0065] Compared with Example 1, the difference of Comparative Example 2 is that the hydrophilic modifier used in step S1.2 is removed, and the other steps remain unchanged to prepare a platelet-rich suspension leukocyte-removing filter membrane, which is recorded as Comparative Example 2.
[0066] Comparative Example 3
[0067] Compared with Example 1, the difference of Comparative Example 3 is that step S2 is removed, and the other steps remain unchanged to prepare a polyethersulfone-polylactic acid filter membrane, which is recorded as Comparative Example 3.
[0068] Comparative Example 4
[0069] Compared with Example 1, the difference of Comparative Example 4 is that the nano titanium dioxide used in step S1.2 is removed, and the other steps remain unchanged to prepare a platelet-rich suspension leukocyte-removing filter membrane, which is recorded as Comparative Example 4.
[0070] Filter membrane physical properties test
[0071] The average pore size, average fiber diameter, porosity and water contact angle of the platelet-rich suspension leukocyte-removing filter membranes prepared in Examples 1-3 and Comparative Example 1 were measured respectively. The results of the physical properties of each group of platelet-rich suspension leukocyte-removing filter membranes are shown in Table 1.
[0072] Table 1:
[0073] Group Average pore size (μm) Average fiber diameter (nm) Porosity (%) Example 1 8.86 542 95 Example 2 9.51 533 93 Example 3 9.33 438 96 Comparative Example 1 11.82 762 87
[0074] As can be seen from Table 1, the platelet-rich suspension leukocyte-removing filter membranes prepared in Examples 1-3 have a narrower average pore size distribution, the average fiber diameter can be controlled below 600 nm, and the porosity is relatively higher, indicating that, compared with the traditional single-nozzle electrospinning process, the polyethersulfone-polylactic acid filter membrane obtained by the coaxial electrospinning process is used to prepare the platelet-rich suspension leukocyte-removing filter membrane, which can control the fiber diameter below 600 nm, and the filter membrane has a narrow pore size distribution and a high porosity, which is beneficial to improving the filtration rate of leukocytes.
[0075] Hydrophilic performance test
[0076] The water contact angles of the platelet-rich suspension leukocyte-removing filter membranes prepared in Examples 1-3 and Comparative Example 2 and the polyethersulfone-polylactic acid filter membrane prepared in Comparative Example 3 were measured using a contact angle tester. The water contact angle measurement results of each group of platelet-rich suspension leukocyte-removing filter membranes are shown in Table 2.
[0077] Table 2:
[0078] Group Water contact angle (°) Example 1 55 Example 2 53 Example 3 58 Comparative Example 2 73 Comparative Example 3 65
[0079] As can be seen from Table 2, the water contact angles of the platelet-rich suspension leukocyte-removing filter membranes prepared in Examples 1-3 are all less than 60°, and the hydrophilic properties are significantly better than those of Comparative Examples 2-3, indicating that the addition of a hydrophilic modifier and the grafting modification of the polyethersulfone-polylactic acid filter membrane surface with a vinyl pyrrolidone-acrylamide copolymer can effectively improve the hydrophilic properties of the platelet-rich suspension leukocyte-removing filter membrane.
[0080] Filtration performance test
[0081] The platelet-rich suspension leukocyte-removing filter membranes prepared in Examples 1-3 and Comparative Examples 1-2 and the polyethersulfone-polylactic acid filter membrane prepared in Comparative Example 3 were stacked into 5 layers to prepare a PF type leukocyte filter. 200 mL of platelet-rich suspension was filtered respectively. The platelet suspension volume, platelet concentration and leukocyte count before and after filtration were recorded, and the platelet recovery rate and leukocyte removal rate were calculated. The results are shown in Table 3.
[0082]
[0083] Where P h is the platelet concentration after filtration, P q is the platelet concentration before filtration, V h is the volume of platelet suspension after filtration, V q is the volume of platelet suspension before filtration.
[0084]
[0085] Wherein L0 is the number of white blood cells contained in the platelet-rich suspension before filtration, and L1 is the number of white blood cells contained in the platelet-rich suspension after filtration.
[0086] Table 3:
[0087] Group Platelet recovery rate (%) Leukocyte removal rate (%) Example 1 95.90 99.81 Example 2 95.05 99.68 Example 3 95.73 99.02 Comparative Example 1 89.71 92.94 Comparative Example 2 80.74 91.13 Comparative Example 3 84.73 93.54
[0088] As can be seen from Table 3, after the platelet-rich suspension leukocyte-removing filter membrane prepared in Examples 1-3 was prepared into a PF type leukocyte filter, the platelet recovery rate in the platelet-rich suspension reached 95%, and the leukocyte removal rate reached 99%, indicating that in the preparation process of the platelet-rich suspension leukocyte-removing filter membrane, the coaxial electrospinning process, the addition of a hydrophilic modifier, and the grafting modification of the polyethersulfone-polylactic acid filter membrane surface with a vinyl pyrrolidone-acrylamide copolymer can effectively improve the platelet recovery rate and leukocyte removal rate of the platelet-rich suspension leukocyte-removing filter membrane.
[0089] Antibacterial performance test
[0090] The concentration is 10 7 CFU / mL of Staphylococcus aureus solution was divided into 5 parts as bacterial solution samples, each of which was 2mL. The platelet-rich suspension leukocyte-removing filter membranes prepared in Examples 1-3 and Comparative Example 4 were placed in 4 of the bacterial solution samples as experimental groups, and the remaining 1 bacterial solution sample was used as a control group. The 5 bacterial solution samples were cultured in a 37°C incubator for 24 hours, and then the bacterial solution samples of each group were diluted 10 times with phosphate buffered saline with pH = 7.4. 0.2mL was taken from each diluted bacterial solution sample and smeared on their respective nutrient agar medium (wherein the nutrient agar medium was prepared by agar and deionized water at a mass ratio of 1:30), and cultured at 37°C for 24 hours. The antibacterial rate was calculated by counting the bacterial colonies, and the results are shown in Table 4.
[0091] The antibacterial rate calculation formula is:
[0092] Where C0 is the number of bacterial colonies in the control group, and C1 is the number of bacterial colonies in the experimental group.
[0093] Table 4:
[0094] Group Staphylococcus aureus inhibition rate (%) Example 1 99.6 Example 2 99.8 Example 3 99.5 Comparative Example 4 24.2
[0095] As can be seen from Table 4, after the platelet-rich suspension leukocyte-removing filter membrane prepared in Examples 1-3 was in contact with the bacterial solution for 24 hours, its antibacterial rate against Staphylococcus aureus could reach more than 99%, and the antibacterial effect was obvious, indicating that the addition of nano-titanium dioxide can effectively improve the antibacterial performance of the platelet-rich suspension leukocyte-removing filter membrane, which is beneficial to reducing the risk of bacterial contamination.
[0096] It should be understood that those skilled in the art can make improvements or changes based on the above description, and all such improvements and changes should fall within the scope of protection of the appended claims of the present invention. Parts not described in detail in this specification belong to the prior art known to those skilled in the art.
Claims
1. A method for preparing a leukocyte-removing filter membrane for platelet-rich suspension, characterized in that: The steps include: S1: Preparation of polyethersulfone-polylactic acid filter membrane, dissolving 15-30g polyethersulfone in 50-150g organic solvent A to obtain a polyethersulfone solution, adding 10-20g polylactic acid, 0.3-1g nano-titanium dioxide and 0.5-2g hydrophilic modifier into 50-150g organic solvent B and stirring to obtain a polylactic acid solution, using a coaxial electrospinning process, using the polyethersulfone solution and the polylactic acid solution to simultaneously spin, to prepare a polyethersulfone-polylactic acid filter membrane with polyethersulfone as the core layer and polylactic acid as the skin layer; S2: Preparation of platelet-rich suspension leukocyte-removing filter membrane, dissolve 5-10g vinyl pyrrolidone and 10-20g acrylamide in 800-1000mL deionized water to obtain a mixed solution, completely immerse the polyethersulfone-polylactic acid filter membrane in the mixed solution, drop an initiator into the mixed solution immersed in the polyethersulfone-polylactic acid filter membrane, the initiator amount is 3-6% of the total mass of vinyl pyrrolidone and acrylamide, seal the reaction, and after the reaction is completed, filter, rinse and dry to obtain a platelet-rich suspension leukocyte-removing filter membrane.
2. The method for preparing a leukocyte-removing filter membrane for platelet-rich suspension according to claim 1, characterized in that: Step S1: Preparation of polyethersulfone-polylactic acid filter membrane, specifically comprising the following steps: S1.1: 15-30 g of polyethersulfone is placed in 50-150 g of organic solvent A, and magnetically stirred at 200-600 rpm for 20-50 min until the polyethersulfone is completely dissolved to obtain a polyethersulfone solution; S1.2: 10-20 g of polylactic acid, 0.3-1 g of nano-titanium dioxide and 0.5-2 g of a hydrophilic modifier are placed in 50-150 g of an organic solvent B, and magnetically stirred at 200-600 rpm for 20-50 min until the polylactic acid and the hydrophilic modifier are completely dissolved to obtain a polylactic acid solution; S1.3: Take the polylactic acid solution and the polyethersulfone solution and inject them into the No. 1 syringe and the No. 2 syringe with a capacity of 10 mL respectively, wherein the polyethersulfone solution is injected into the No. 1 syringe and the polylactic acid solution is injected into the No. 2 syringe. Use a PVDF plastic tube to connect the coaxial spinneret, fix the No. 1 syringe and the No. 2 syringe on the injection pump, set the spinning voltage to 10-30KV, the receiving distance to 10-20cm, the propulsion speed to 0.5-1.5mL / h, and use 304 stainless steel as the receiving substrate for collection to obtain a polyethersulfone-polylactic acid filter membrane with polyethersulfone as the core layer and polylactic acid as the skin layer.
3. The method for preparing a leukocyte-removing filter membrane for platelet-rich suspension according to claim 2, characterized in that: The organic solvent A is at least one of dimethylformamide, N,N-dimethylacetamide, dichloromethane, acetone and N-methylpyrrolidone.
4. The method for preparing a leukocyte-removing filter membrane for platelet-rich suspension according to claim 3, characterized in that: The organic solvent B is at least one of N,N-dimethylacetamide, dichloromethane, chloroform, acetone and tetrahydrofuran.
5. The method for preparing a leukocyte-removing filter membrane for platelet-rich suspension according to claim 4, characterized in that: The hydrophilic modifier is at least one of hydroxymethyl cellulose, hydroxyethyl cellulose and hydroxypropyl cellulose.
6. The method for preparing a leukocyte-removing filter membrane for platelet-rich suspension according to claim 5, characterized in that: The particle size of nano titanium dioxide is 20 to 60 nm.
7. The method for preparing a leukocyte-removing filter membrane for platelet-rich suspension according to claim 1, characterized in that: Step S2: Preparation of leukocyte-removing filter membrane for platelet-rich suspension, specifically comprising the following steps: S2.1: Add 5-10g vinyl pyrrolidone and 10-20g acrylamide into a reactor filled with 800-1000mL deionized water, stir magnetically for 10-20min at 200-600rpm to mix evenly, and obtain a mixed solution; S2.2: Immerse the polyethersulfone-polylactic acid filter membrane completely in the mixed solution, introduce nitrogen into the reactor for deoxygenation treatment, and the ventilation time is 20-30min. Then, drop an initiator into the reactor, and the amount of the initiator is 3-6% of the total mass of vinyl pyrrolidone and acrylamide. Then, seal the reactor, and place the reactor in a constant temperature oil bath at 60-80℃ to react for 0.5-2h; S2.3: After the reaction is completed, the polyethersulfone-polylactic acid filter membrane is filtered out of the reactor and rinsed with deionized water for 3 to 5 times. Then, the rinsed polyethersulfone-polylactic acid filter membrane is placed in an oven at 80°C to dry to obtain a platelet-rich suspension leukocyte-removing filter membrane.
8. The method for preparing a leukocyte-removing filter membrane for platelet-rich suspension according to claim 7, characterized in that: The initiator is azobisisobutyronitrile, potassium persulfate, azobisisobutylimidazoline hydrochloride or azobiscyanovaleric acid.
9. A platelet-rich suspension leukocyte removal filtration membrane, characterized in that: The platelet-rich suspension leukocyte-removing filtration membrane is prepared by the method for preparing the platelet-rich suspension leukocyte-removing filtration membrane as described in any one of claims 1 to 8.
10. A platelet-rich suspension leukocyte-removing filtration membrane according to claim 9, characterized in that: The platelet-rich suspension leukocyte-removing filter membrane is stacked into 3 to 10 layers to prepare a PF type leukocyte filter for filtering leukocytes in the platelet-rich suspension and recovering platelets.
Citation Information
Patent Citations
Leukocyte filtration membrane, its manufacturing method and uses
CN104923091B
Platelet leukocyte-depleted filter membrane and preparation method thereof
CN110787647A
Preparation method of antibacterial double-layer hollow fibrous membrane
CN103285740A
Filter material for removing white blood cells in blood and preparation method thereof
CN118326704A
Medical material, medical separation membrane, and blood purifier
US20190209744A1
